Upregulation of Somatostatin Receptor Type 2 Improves (177)Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model

Pancreatic neuroendocrine tumors (PNET) express high levels of somatostatin receptor type 2 (SSTR2), a unique target for both tumor imaging and therapy. This surface expression is lost in metastatic high-grade PNETs, making patients ineligible for SSTR2-targeted (177) Lutetium (Lu)-DOTATATE peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Rupali, Earla, Bhargav, Baidoo, Kwamena E., Zeiger, Martha A., Madigan, James P., Escorcia, Freddy E., Sadowski, Samira M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477832/
https://www.ncbi.nlm.nih.gov/pubmed/37487000
http://dx.doi.org/10.1158/1535-7163.MCT-22-0798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477832/
https://www.ncbi.nlm.nih.gov/pubmed/37487000
http://dx.doi.org/10.1158/1535-7163.MCT-22-0798

Ejemplares similares